Frontlight ResearchEarly access
Taking people in NetherlandsPhase 1
Early safety study of LCA-0321 in people with Graves disease
Tests LCA-0321 in adults who have Graves disease.
Key facts
- Who runs it
- Lycia Therapeutics Inc.
- Where
- 's-Hertogenbosch, Groningen, and Rotterdam, NetherlandsSee the 3 sites
- Trial code
- Registry title
- Phase 1 Single Ascending and Multiple Ascending Dose Study with LCA-0321
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 22 people, planned
- Started
- 2 Apr 2026
- Expected to end
- 1 Sept 2028
- Type of study
- Interventional
- Record updated
- 30 September 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Graves disease for an early study of single and repeated rising doses of LCA-0321.
- Age
- 18 years and older
- Sex
- All sexes
Main reasons for not taking part
- Healthy volunteers cannot join.
Where in Netherlands
- Brain Research Center Den Bosch B.V.'s-Hertogenbosch, NetherlandsTaking people
- CTC Netherlands B.V.Groningen, NetherlandsTaking people
- Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Rotterdam, NetherlandsTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Early safety study of LCA-0321 in people with Graves diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 30 September 2026